Alejandro González Veliz/LinkedIn
Jun 23, 2026, 09:36
Alejandro González Veliz: Key Takeaways from the 2026 ACC/AHA Dyslipidemia Guidelines
Alejandro González Veliz, Interventional Cardiologist at Institute of Cardiology and Cardiovascular Surgery, shared a post on LinkedIn:
“Dyslipidemia management is entering a new era.
The 2026 ACC/AHA Guideline moves beyond LDL-C alone and embraces a more personalized approach to cardiovascular prevention.
- LDL-C goals are back
- Lp(a) should be measured at least once
- ApoB helps uncover residual risk
- Coronary calcium refines risk assessment
- Earlier intervention may change lifelong outcomes
The message is simple: identify risk earlier, treat smarter, and prevent ASCVD before the first event occurs.
Which update do you think will have the greatest impact on your daily practice?
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering